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Abstract
Background Central pontine and extrapontine myelinol-
ysis (CPEPM) is a rare but potentially fatal complication
after orthotopic liver transplantation (OLT). The aim of
this study was to identify risk factors for development of
CPEPM after OLT and to assess patient outcome.
Methods We reviewed the clinical data of 1,378 patients who
underwent OLT between 1987 and 2009 in Geneva, Switzer-
land and Edmonton, Canada. Nineteen patients (1.4 %)
developed CPEPM. We compared their characteristics with
control patients, matched by age, gender, date of OLT, and
MELD score.
Results The 19 patients with CPEPM (7F, mean age
52.1 ± 2 years) had a mean MELD score of 26 ± 2.2.
Before OLT, patients who develop CPEPM presented more
frequently low (<130 mmol/l; p < 0.04) and very low
(<125 mmol/l; p < 0.009) sodium than controls. In
patients developing CPEPM, the number of platelet units
and fresh frozen plasma transfused during surgery was
higher (p = 0.05 and 0.047), hemorrhagic complications
were more frequent after OLT (p = 0.049), and variations
of sodium before and after OLT were higher (p = 0.023).
The association of >2 of these conditions were strongly
associated with CPEPM (p = 0.00015). Mortality at 1 year
of patients developing CPEPM was higher (63 vs. 13 %,
p < 0.0001).
Conclusions High MELD score patients undergoing
OLT, receiving massive perfusions of Na-rich products,
experiencing surgery-related hemorrhagic complication
and important fluctuations of Na are at risk of developing
CPEPM. Therefore careful monitoring of natremia in the
perioperative period and use of water-free perfusion in case
of massive blood-products transfusion are critical points of
this patient management.
Keywords Orthotopic liver transplantation  MELD 
Neurological complications 
Central pontine and extrapontine myelinolysis 
Hyponatremia  Hemorrhagic complications  Mortality
Introduction
First described by Adams et al. [1] in 1959 central pontine
myelinolysis (CPM) is a symmetrically demyelinating
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lesion of the pons often associated with demyelination of
other areas of the central nervous system (extrapontine
myelinolysis, EPM; [2]). Occasionally reversible [3] or
asymptomatic [3, 4] this disease is often associated with
severe neurological symptoms frequently progressing to
death or permanent neurological damage. Diagnosis is
made through correlation of clinical findings with neuro-
imaging, mainly magnetic resonance imaging (MRI).
Radiologic findings may appear days to weeks after the
onset of symptoms and are not always correlated neither to
symptoms severity nor to clinical evolution [5, 6]. The
exact etiology of CPM remains unclear, but it is supposed
that any rapid and important osmotic shifts could induce
injury to the endothelial cells resulting in their tight junc-
tions break and the release of myelinotoxic factors that can
mediate oligodendroglial injury and dissolution of the
myelin sheaths.
The incidence of CPM after orthotopic liver transplant
(OLT) varies from 0.29 to 11.4 % in observational studies
[6–12] to 28.6 % in autopsy series [13–18]. Liver trans-
plant patients represent the third largest group of CPM
(17.4 %), after chronic alcoholic patients (39.4 %) and
patients who undergo quick correction of hyponatremia
(>0.5 mmol/l/h; 21.5 %; [19]), with about 165 docu-
mented cases published from 1986 to 2009 [4–12, 14, 20–
32]. The majority of these publications are case reports and
retrospective clinical observational studies without control
group.
Hyponatremia or its rapid correction is a recognized
cause of CPM but, after OLT, some specific risk factors are
suspected such as pre-OLT encephalopathy, previous
alcoholism, severe malnutrition and ionic disorders asso-
ciated with end-stage cirrhosis and the use of diuretics.
Perioperative volume of blood products infused [10, 11]
and, after OLT, the use of calcineurin inhibitors, CNIs [33,
34] may be a risk factor to develop neurological compli-
cations [24, 27, 30].
The aim of this study was to identify risk factors for
development of clinically relevant central pontine and
EPM (CPEPM) after OLT and to assess patient outcome.
Methods
Patient Selection
We retrospectively reviewed the clinical data of 1,378
patients who underwent OLT between July 1987 and
December 2009 in the Geneva, Switzerland (n = 523) and
Edmonton, Canada (n = 855) liver transplant programs.
The study was approved by the Ethics Committee of
both centers.
CPEPM diagnosis was made on neurological symptoms
correlated with brain MRI. Neurological symptoms sug-
gestive of CPEPM were progressive lethargy, flaccid
quadriparesis, decreased reflexes, dysarthria, dysphagia,
aphasia, ophthalmoplegia, akinesia, pyramidal syndrome,
choreoathetosis, catatonia, or ataxia. In association with
these symptoms, CPEPM was diagnosed by MRIs showing
hyperintense signals on T2-weighted and FLAIR imaging
in the central pons, thalamus, basal ganglia, cerebellum and
subcortex, without enhancement or mass effect [22, 35].
Increased signals on diffusion-weighted imaging in the
same regions were also considered [36]. Patients with other
neurological findings such as stroke or absence of typical
MRI imaging were excluded.
Nineteen patients were diagnosed as having CPEPM. For
each of these patients, we selected two control patients with-
out CPEPM, matched by age ± 10 years, gender, date of
OLT ± 18 months, MELD score [37] calculated as (0.957
ln(creatinine) + 0.378 ln(bilirubin) + 1.120 ln(international
normalized ratio of prothrombin) + 0.643) 9 10(36) ±
5 points, emergency status, and compared their clinical and
biochemical parameters before, during, and after OLT.
Risk Factors for CPEPM After OLT
To determine risk factors for CPEPM after OLT, we
compared the CPEPM group (n = 19) with the control
group (n = 38) for the following clinical and biochemical
parameters.
Pre-operative Clinical Parameters on the Day of OLT
Gender, body mass index (BMI), indication for OLT,
CHILD score at OLT, encephalopathy at OLT graded from
1 to 3, and ascites at OLT graded from 1 to 3.
Pre-operative Biochemical Parameters (Just Before OLT)
Creatinine, INR, bilirubin, albumin, Hb, platelets, white
blood cells (WBCs), glucose, Na, K, Mg, ASAT, ALAT,
GGT, and alkaline phosphatase.
Donor’s Data
Age, gender, and BMI.
Per-operative Clinical Parameters
Warm and cold ischemia time, number of red blood cells
(RBCs), platelet units and fresh frozen plasma (FFP) trans-
fused during surgery, episodes of hypotension defined as
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mean arterial pressure <60 mmHg, and episodes of hyper-
tension defined as mean arterial pressure >100 mmHg.
Post-operative Clinical Parameters
Delay between OLT and clinical CPEPM onset, cerebral
MRI description in case of CPEPM, CPEPM evolution,
cause of death and its delay after CPEPM and OLT, day of
extubation, immunosuppression (use of steroids and doses,
blood levels of tacrolimus, cyclosporine, rapamune, ever-
olimus), immunosuppression switch after diagnosis of
CPEPM, hemorrhage after OLT requiring transfusion or
surgery, post-OLT metabolic acidosis (pH < 7.39 and
normal pCO2 ), post-OLT hypoxemia (arterial pO2 < 8 kPa
on ABG while in ICU), post-OLT hypercapnia (arterial
pCO2 > 6 kPa on ABG while in ICU), and occurrence of
rejection, treatment of rejection and its delay before
CPEPM.
Post-operative Biochemical Parameters
Highest value between OLT and clinical CPEPM or
highest value during the 15 days following OLT for the
controls: Na, K, osmolality, AST, ALT, WBC, creatinine
and CNI and m-TOR inhibitors trough levels.
Lowest value between OLT and clinical CPEPM or
lowest value during the 15 days following OLT for the
controls: Hb, platelets, albumin, glucose, Na, and Mg.
Statistical Analysis
Numerical data are expressed as percentage (%), mean with
standard deviation (SD) or median with range, as appro-
priate. Quantitative variables were compared using Student
t test or Mann–Whitney test as needed. Pearson v2 or Fisher
exact test was used for qualitative parameters. Survival
rates were evaluated using Kaplan–Meier curves and log-
rank test. Values of p < 0.05 were considered statistically
significant. Data analysis was performed using the SPSS
statistical software version 20.0 (IBM SPSS Statistics).
Results
Out of 1,378 patients who underwent OLT from 1987 to
2009, 19 (1.4 %) developed clinical CPEPM. There were 7
women and 12 men, with a mean age of 52.1 ± 2 years, a
mean MELD score of 26 ± 2.2, and a median MELD score
of 24 (11–40), a median CHILD score of 13 (10–14).
Indications for OLT were: alcoholic cirrhosis in 9 patients
(47 %), HCV cirrhosis in 4 (21 %), primary biliary cir-
rhosis (PBC) in 2 (10.5 %), fulminant hepatitis in 1 (5 %),
and other causes of cirrhosis in 3 (1 HBV cirrhosis, 1
idiopathic cirrhosis and 1 AIAD; 16.5 %). Two of these
patients had a hepatocellular carcinoma, HCC (Table 1).
Pre-operative Clinical and Biochemical Parameters
Patients and controls were similar in terms of pre-operative
clinical and biochemical parameters. INR values tended to
be higher in patients who developed CPEPM after OLT
(p = 0.059). Patients who developed CPEPM presented
more frequently low (<130 mmol/l; 47.4 vs. 21 %,
p < 0.04) and very low (<125 mmol/l; 26.3 vs. 0 %,
p < 0.009) plasma sodium than controls (Table 2).
Donors Parameters
Donors parameters such as BMI (25.3 ± 1.2 vs. 24.6 ±
0.8 kg/m2) and age (48 ± 5.5 vs. 45.1 ± 3 years) were
similar.
Per-operative Clinical Parameters
Per-operative clinical parameters showed that warm and
cold ischemia time, episodes of hypertension (mean arterial
pressure >100 mmHg), and episodes of hypotension
(mean arterial pressure <60 mmHg) did not differ
between the two groups. The number of platelet units and
FFP transfused during surgery was significantly higher in
patients who developed CPEPM (8.3 ± 6 vs. 4 ± 0.8,
p = 0.05, and 19.5 ± 5 vs. 10.6 ± 1.4, p = 0.047). The
number of RBCs units was higher in patients with CPEPM
but did not reach statistical significance (Table 3).
Table 1 Cases and controls characteristics
Cases Controls p
Geneva (n) 7 14
Edmonton (n) 12 24
Total (n) 19 38
Gender F/M 7/12 (37 %) 13/25 (34 %) 0.844
Age at CPM mean (years) 52.1 ± 2 52.6 ± 1.2 0.827
MELD mean ± SD
Median (range)
26 ± 2.2
24 (11–40)
25.6 ± 1.3
24.5 (11–41)
0.872
CHILD median (range) 13 (10–14) 12 (8–15)
OLT indications
OH
HCV
PBC
Fulminant hepatitis
Others
HCC
9 (47 %)
4 (21 %)
2 (10.5 %)
1 (5 %)
3 (16.5 %)
2
14 (37 %)
9 (24 %)
6 (16 %)
2 (5 %)
7 (18 %)
4
0.856
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Post-operative Clinical Parameters
Six of the 19 patients with CPEPM remained intubated 2–
30 days after the first neurocognitive impairment. Cyclo-
sporine was used in 12 patients (63 %) who developed
CPEPM and in 42 % of controls (ns). Tacrolimus was used
in 37 % of patients who developed CPEPM and in 53 % of
controls (ns). Steroids were used in 79 % of patients of
both groups. Hemorrhagic complications requiring trans-
fusion or surgery occurred in 32 % (6/19) of patients who
developed CPEPM and in 10.5 % (4/38) of controls
(p = 0.049). Metabolic acidosis (pH <7.39 and normal
pCO2 ), hypoxemia (arterial pO2 <8 kPa on ABG while in
ICU), and hypercapnia (arterial pCO2 >6 kPa on ABG
while in ICU) did not differ between the two groups after
OLT (Table 4). Episodes of rejection did not play any role
in the etiology of CPEPM as the majority of them occurred
usually after the apparition of neurological symptoms.
Post-operative Biochemical Parameters
The percentage of patients with high CNI trough levels
(cyclosporinemia >300 lg/l and tacrolimus trough lev-
els >15 lg/l) was similar in both groups (58 vs. 50 %: ns).
The variations of Na before and in the first days after OLT
were higher in patients with CPEPM than in controls
(15.9 ± 1.9 vs. 11.1 ± 0.9 mmol/l, p = 0.023). Patients
with CPEPM tended to undergo quicker correction
(C0.5 mmol/l/h) of hyponatremia during the first 24 h after
OLT (7/19: 36.8 % vs. 6/38: 15.8 %, p = 0.07). The peak
values of osmolarity, potassium, AST, ALT, creatinine,
and WBC after OLT were similar in both groups. The
lowest value of Hb, platelets, albumin, glucose, Na, Mg
between OLT and clinical CPEPM or lowest value during
the 15 days following OLT for the controls was similar in
both groups (Table 4).
Post-operative Clinical and Radiological Parameters
The neurological manifestations of CPEPM occurred in
9.53 ± 6.56 days after OLT, the earliest 3 days after and
the latest 25 days after OLT. Brain imaging was performed
within a median of 6 days (1–33) after the first symptoms.
MRI features of patients with suspected CPEPM are
detailed in Table 5. Majority of patients show pontine and
extrapontine lesions on T2/FLAIR. Eleven patients (58 %)
were switched to m-TOR inhibitors after CPEPM, CNI
levels were reduced for the other eight patients. Mortality
at 1 year of patients developing CPEPM was significantly
increased (63 vs. 13 %, p < 0.0001; Fig. 1).
Risk Factors of Developing CPEPM
Severe and very severe hyponatremia, transfusion of C4
platelet units (median of platelet units transfused in patients
with CPEPM), of C12 FFP (median of FFP transfused in
patients with CPEPM), hemorrhagic complications and
increasing of Na C12 mmol (median of Na variation after
OLT in patients with CPEPM) in the post-operative course
were identified as risk factors for developing CPEPM. Only
8 % (3/38) of the controls presented >2 of these risks
compared with 50.65 % (10/19) of patients with CPEPM.
The association of C3 of these risk factors was strongly
associated with CPEPM occurrence (p = 0.00015).
Table 2 Pre-operative clinical and biochemical parameters
Mean ± SD Cases Controls p
INR 2.86 ± 0.6 1.91 ± 0.14 0.059
Creatinine (mmol/l) 132 ± 16 135 ± 12.5 0.829
Bilirubin (mmol/l) 264.3 ± 61.6 276.2 ± 44 0.710
Albumin (g/l) 28.2 ± 1.5 31.1 ± 1.2 0.140
Hemoglobin (g/l) 95.4 ± 4.4 96.3 ± 3.7 0.493
Platelets (U/ml) 55.8 ± 5 66.8 ± 4 0.223
Glucose (mmol/l) 8.9 ± 2.4 6.3 ± 0.3 0.933
Sodium (mmol/l) 133 ± 2.2 134.8 ± 0.9 0.623
Na <130 mmol/l, n (%) 9 (47.4) 8 (21) 0.04
Na <125 mmol/l, n (%) 5 (26.3) 0 0.009
Potassium (mmol/l) 4.17 ± 0.1 4.4 ± 0.13 0.154
Magnesium (mmol/l) 0.71 ± 0.06 0.8 ± 0.07 0.360
AST (IU/l) 94.7 ± 28 113 ± 44 0.393
ALT (IU/l) 159 ± 37 162 ± 52 0.332
Ascites 1/2/3a 1/9/9 6/11/21 0.284
Encephalopathyb 0/1–2/3–4 1/9/9 6/16/16 0.521
BMI (kg/m2) 25.3 ± 1.2 24.6 ± 0.8 0.733
a According to CHILD score
b According to New Haven score
Table 3 Perioperative parameters
Mean ± SD Cases Controls p
Hypotension (TAM <60 mmHg)
(%)
53 37 0.336
Hypertension (TAM >100 mmHg)
(%)
12.5 30.5 0.145
Cold ischemia time (min) 488.6 ± 45 483.8 ± 24 0.463
Warm ischemia time (min) 57.4 ± 4 56 ± 2 0.802
Red blood cells (units) 14 ± 4 8 ± 1.2 0.08
Fresh frozen plasma (units) 19 ± 5 10.6 ± 1.4 0.047
Thrombapheresis (units) 8.3 ± 6 4 ± 0.8 0.05
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Discussion
Our study, the largest published till date, using homoge-
nous control population including patients with similar age,
gender, MELD score, and date of transplantation, shows
that CPEPM after OLT results of an addition of risk factors
leading to important shifts in plasma sodium concentration
in the first days after surgery. Our data confirm that severe
hyponatremia at the moment of transplantation and
important peri-operative serum Na variation are risk factors
of developing CPEPM and reveal the role played by the
number of FFP units and thrombapheresis transfused dur-
ing surgery and by post-operative hemorrhagic
complications requiring transfusion or surgery. The addi-
tion of more than two of these conditions was strongly
associated with CPEPM occurrence. Pre-operative INR
values tend to be higher in patients who develop CPEPM
and may have increased the risk of surgery-related hem-
orrhagic complications and massive transfusion. This
confirms the conclusion of Lee et al. [11] that the use of
massive transfusion and volume replacement during sur-
gery may favor the occurrence of CPM. Thrombapheresis,
FFP and RBC units are rich in sodium and cause rapid
serum sodium shift.
In the present report, patients with CPEPM had signif-
icantly greater and tended to have quicker (C0.5 mmol/l/h
in the first 24 h) sodium fluctuation after OLT. We failed to
demonstrate that quick Na correction occurred only in the
first 24 h after OLT probably because more than one-third
of the patients who developed CPEPM underwent re-
operation and/or transfusions after transplantation causing
Na fluctuation later in the post-transplantation course.
There was a significantly larger percentage of patients
with severe (<130 mmol/l) and very severe (<125 mmol/l)
hyponatremia in the group with CPEPM as compared with
the patients without CPEPM despite the fact that the mean
pre-operative plasma sodium concentrations were similar in
case and control groups. CPEPM may occur in patients with
relatively normal serum sodium: in presence of an osmotic
challenge, neuroglia activate energy-dependant cell surface
pumps (e.g., Na–K ATPase) to rapidly counteract the elec-
trolyte derangement. In patients with liver failure or in case
of malnutrition, it is postulated that glia cells may inherently
lack a plentiful supply of glucose or glycogen, hence rela-
tively minor osmotic derangements might lead to a rapid
depletion of cellular energy supply and cell death [38, 39]. A
lack of adequate concentrations of organic osmolytes pre-
disposes the brain to osmotic injury [40].
Hyponatremia is a common complication of advanced
cirrhosis mainly related to impairment in the renal capacity
to eliminate solute-free water causing a reduction in serum
sodium concentration and hypo-osmolality. This dilutional
hyponatremia reflects hemodynamical dysfunction associ-
ated with severe portal hypertension [41]. In addition, the
use of diuretics in patients with hypervolemic hyponatre-
mia is another cause of hyponatremia in this population of
patients with advanced cirrhosis. According to the
increased risk of developing CPEPM in case of severe
hyponatremia before OLT, diuretics should be used with
caution in patients with plasma sodium B130 mmol/l.
Albumin perfusion rich in sodium and known to inhibit
antidiuretic hormone should be encouraged before OLT
and more effective treatment of dilutional hyponatremia
such as vaptan should be studied in patients on waiting list.
Peri-operative management of patients undergoing liver
transplantation should include careful monitoring of
sodium plasma concentration and preference of water-free
perfusion in case of massive transfusion of blood products.
Table 4 Post-operative
parameters
a Highest value between OLT
and clinical CPEPM or highest
value during the 15 days
following OLT for the controls
Cases Controls p
Immunosuppression 0.245
Tacrolimus, n (%) 7 (37) 20 (53)
Cyclosporine, n (%) 12 (63) 16 (42)
Sirolimus, n 1
No immunosuppression, n 1
Hemorrhagic complications, n (%) 6 (32) 4 (10.5) 0.049
Acidosis (pH < 7.39 and normal pCO2 ), n (%) 7 (36) 15 (39.5) 0.905
Hypoxemia (arterial pO2 <8 kPa), n (%) 7 (36) 8 (21.6) 0.302
Hypercapnia (arterial pCO2 >6 kPa), n (%) 6 (31) 8 (21.6) 0.524
Na changes >0.5 mmol/h in the first 24 h after OLT, n (%) 7 (36.8) 6 (15.8) 0.07
Na changes before–after OLTa (mmol/l), mean ± SD 15.9 ± 1.9 11.1 ± 0.9 0.023
Peak ALAT value after OLT (mmol/l), mean ± SD 848.5 ± 164.4 1,061.2 ± 175.4 0.617
Peak ASAT value after OLT (UI/l), mean ± SD 1,157.7 ± 191.6 1,469 ± 200.6 0.488
Peak osmolarity value after OLT, mean ± SD 314.2 ± 7 308 ± 4 0.357
CNI trough levels: FK >15 or CyA >300 lmol/l (%) 58 50 0.851
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Table 5 MRI features of patients with suspected CPEPM
Patients Time of
symptoms
after OLT
(days)
Type of symptoms Time of
MRI after
OLT
(days)
MRI features Pontine-
brain
stem
lesions
Extrapontine-
brain stem
lesions
Outcomes
T1 T2/
FLAIR
DWI
1 8 Complete aphasia
Flaccid tetraparesia
14, 17 - + - No Yes Speaking improvement
Death at 4 months recurrent
disease
2 23 Altered consciousness 51 - ++ - Yes Yes Death at 2 months multisystem
failure
3 5 Dysarthria, dysphagia 8, 18 Able to speak 1 week later, by
4 months able to be up with
walker and discharged from
hospital
Death at 8 years sepsis
4 6 Locked in syndrome 7 - +++ - Yes Yes Understand verbal communication,
quadriplegia
Death at 4 months sepsis,
multisystem failure
5 3 Seizure 16 - ++ - Yes No Alive
6 7 Coma, seizure 7, 18 + +++ - Yes Yes No significant clinical
improvement
Death at 4 months treatment
withdrawal
7 6 Respiratory failure,
coma
20 - ++ - Yes Yes Clinical improvement, extubation,
remained confused
Death at 2 months cardiovascular
8 5 Confusion 34 - +++ - Yes No No significant clinical
improvement
Death at 3 months subarachnoid
hemorrhage
9 6 Seizure, coma 12 - + + Yes Yes Waked up at 5 weeks, walked at
7 weeks, discharged from
hospital at 5 month
Alive
10 16 Dysarthria 19 - + - Yes No Alive
11 12 Altered consciousness 18 - +++ + Yes Yes Tracheotomy, persistent seizure
despite treatment, open eyes
Death at 9 months malignancy
12 17 Hand and arm tremor 17 - ++ + Yes Yes Death at 7 months pulmonary
disease
13 4 Aphasia, tetraparesia 9, 23 - ++ + Yes Yes No significant clinical
improvement
Death at day 46 respiratory arrest
on obstruction of the canula
14 5 Seizure, flaccid
tetraparesia
10 - ++ ++ Yes No Coma
Death at day 16
15 7 Seizure 11, 20 - +++ - Yes No Persistent dysarthria, psycho-motor
slowering
Death at month 4 chronic rejection
16 9 Coma, left
extrapyramidal
syndrome, right
pyramidal syndrome
15, 53 - +++ + Yes Yes Persistent dysarthria, psycho-motor
slowering, dependent for
everyday life
Death at month 11 HCV recurrence
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In the pre-operative clinical data we did not find any
difference in terms of encephalopathy, ascites, and BMI.
Indications for OLT were similar in both groups and,
despite the fact that CPM has often been associated with
alcohol consumption, this study shows that neurological
complications could occur equally in patients with end-
stage liver diseases of any etiology.
Most of the patients with CPEPM had high MELD score
(mean 26 ± 2.2, median 24, range 11–37) and were rep-
resentative of the general population waiting for OLT; the
decreased liver function was not by itself a risk factor to
develop CPEPM as the controls had similar MELD score.
Recently, Lee et al. [11] published the first and unique
case–control study with cases of CPM and age-, gender-,
and date of operation-matched controls. They suggested
that the MELD–Na score, as indicator of severe end-stage
cirrhosis, predicts the occurrence of CPM. As their patients
were not matched for the MELD score, they concluded that
patients with more severe liver dysfunction had higher risk
to develop CPM. But, as shown in our study, the MELD
score is not a strong predictor of CPEPM occurrence. Still
the presence of more severe patients on the waiting list will
potentially increase the incidence of CPEPM after liver
transplantation.
We did not observe any association among CPEPM, the
type of immunosuppression, and high CNI trough levels.
Still, some reports incriminate CNI in the occurrence of
CPEPM [42]. We cannot exclude that cyclosporine or ta-
crolimus played a role in our patients neurological
deterioration. Nevertheless none of our patients with sus-
pected CPEPM showed the classical but controversial
lesions described in CNI toxicity, such as the posterior
reversible encephalopathy syndrome or diffuse
microangiopathy.
CPEPM was associated with a significantly higher
mortality rate. Despite the fact that CPEPM was not the
direct cause of every death, it probably increases the risk of
pulmonary infections, sepsis, and multisystem failure. In
addition, severe neurological symptoms probably changed
the general way to take care of specific pathology such as
HCV recurrence.
Table 5 continued
Patients Time of
symptoms
after OLT
(days)
Type of symptoms Time of
MRI after
OLT
(days)
MRI features Pontine-
brain
stem
lesions
Extrapontine-
brain stem
lesions
Outcomes
T1 T2/
FLAIR
DWI
17 3 Coma 36 - ++ + Yes Yes Clinical improvement with residual
confusion
Discharge from hospital after
4 months
Persistent cerebellar syndrome
Alive and independent
18 4 Seizure, altered
consciousness
25 - +++ + Yes No Discharge from hospital after 11
months, lived in a medical home
Persistent spastic tetraparesia,
cerebellar ataxia, severe dysarthria
Death at 8 years lung carcinoma
19 11 Aphasia, apraxia,
extrapyramidal
syndrome
32 - +++ - No Yes Discharge from hospital after
3 months
Persistent dysarthria
Death at 7 years colic carcinoma
Majority of patients show pontine and extrapontine lesions on T2/FLAIR
Fig. 1 Survival in the two groups, log-rank p < 0.001
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Our study is the largest one published till date reporting
patients who developed CPEPM after OLT and the second
to be controlled. However, this work has several limita-
tions. It is a retrospective analysis covering 22 years of our
liver transplantation program and therefore lacking inter-
esting data such as osmolality before and after OLT,
fluctuation of serum sodium during surgery, total fluid
infusion, etc.
Our patients were selected on a retrospective mode
based on the development of suggestive neurological
symptoms, confirmed by a typical image of demyelinisa-
tion on MRI. Controls had no MRI imaging and we cannot
exclude subclinical CPEPM. Findings from autopsy series
suggest that asymptomatic or mildly symptomatic CPEPM
may be significantly more common than suspected in OLT
patients. Therefore only a prospective study with pre- and
post-transplant MRI and neurological follow-up will be
able to determine the real incidence of CPEPM after OLT
and the actual risk factors for this rare but potentially fatal
complication. However, CPEPM is such a rare event after
OLT that a prospective analysis would be difficult to
obtain.
Conclusion
Our study shows that in high MELD score patients
undergoing OLT, severe hyponatremia, massive perfusions
of Na-rich products, post-operative hemorrhagic compli-
cations and important fluctuations of serum sodium are risk
factors of developing CPEPM. The addition of more than
two of these conditions is strongly predictive of CPEPM.
This rare but potentially severe complication, albeit more
frequent in case of severe hyponatremia, may concern
patients with normal or near normal serum sodium con-
centration in presence of other risk factors. We can
postulate that the incidence of CPEPM will increase in the
future. Indeed, patients with higher MELD scores and
consequently increased risk of surgery-related hemorrhagic
complication, massive transfusion, or sodium shifts are
now selected for OLT. Therefore, diuretic drugs should be
used with caution before OLT in patient with hyponatre-
mia, effective drugs against dilutional hyponatremia such
as vaptan should be studied in this specific situation,
careful monitoring of natremia in the perioperative period,
and use of water-free perfusion in case of massive blood-
products transfusion are critical points of this patient
management.
Acknowledgments Christian Toso was supported by the Swiss
National Science Foundation (SCORE Grant 3232230-126233).
Conflict of interest Isabelle Morard, Yvan Gasche, Mark Knet-
eman, Christian Toso, Ariane Mentha, Glenda Meeberg, Gilles
Mentha, Norman Kneteman, and Emiliano Giostra declare that they
have no conflict of interest.
References
1. Adams RD, Victor M, Mancall EL. Central pontine myelinolysis: a
hitherto undescribed disease occurring in alcoholic and malnour-
ished patients. AMA Arch Neurol Psychiatry. 1959;81(2):154–72.
2. Wright DG, Laureno R, Victor M. Pontine and extrapontine
myelinolysis. Brain. 1979;102:361–85.
3. Pfister HW, Einhaupl KM, Brandt T. Mild central pontine mye-
linolysis: a frequently undetected syndrome. Eur Arch Psychiatry
Neurol Sci. 1985;235(3):134–9.
4. Kato T, Hattori H, Nagato M, et al. Subclinical central pontine
myelinolysis following liver transplantation. Brain Dev.
2002;24(3):179–82.
5. Winnock S, Janvier G, Parmentier F, et al. Pontine myelinolysis
following liver transplantation: a report of two cases. Transpl Int.
1993;6:26–8.
6. Fryer JP, Fortier M, Metrakos P, et al. Central Pontine Myeli-
nolysis and Cyclosporine neurotoxicity following liver
transplantation. Transplantation. 1996;61:658–61.
7. Bonham CA, Dominguez EA, Fukui MB, et al. Central nervous
system lesions in liver transplant recipients: prospective assess-
ment of indications for biopsy and implications for management.
Transplantation. 1998;66(12):1596–604.
8. Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME,
Miller CM. Central nervous system complications in liver
transplant recipients-incidence, timing, and long-term follow-up.
Clin Transplant. 2002;14:1–7.
9. Yu J, Shu-Sen Z, Ting-Bo L, Yan S, Wei-Lin W, Qing-Hong K.
Possible causes of central pontine myelinolysis after liver trans-
plantation. World J Gastroenterol. 2004;10(17):2540–3.
10. Kim BS, Lee SG, Hwang S, et al. Neurologic complications in
adult living donor liver transplant recipients. Clin Transplant.
2007;21:544–7.
11. Lee EM, Kang JK, Yun SC, et al. Risk factors for central pontine
and extrapontine myelinolysis following orthotopic liver trans-
plantation. Eur Neurol. 2009;62(6):362–8.
12. Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant
hyponatremia on outcome following liver transplantation. Hepa-
tology. 2009;49(5):1610–5.
13. Wszolek ZK, McComb RD, Pfeiffer RF, et al. Pontine and ex-
trapontine myelinolysis following liver transplantation.
Relationship to serum sodium. Transplantation. 1989;48(6):
1006–12.
14. Estol CJ, Faris AA, Martinez AJ, Ahdab-Barmada M. Central
pontine myelinolysis after liver transplantation. Neurology.
1989;39:493–8.
15. Boon AP, Adams DH, Buckels JA, McMaster P. Neuropatho-
logical findings in autopsies after liver transplantation. Transplant
Proc. 1991;23:1471–2.
16. Ferreiro JA, Robert MA, Townsend J, Vinters HV. Neuropatho-
logic findings after liver transplantation. Acta Neuropathol.
1992;84(1):1–14.
17. Singh N, Yu VL, Gayowski T. Central nervous system lesions in
adult liver transplant recipients: review with implications for
management. Medicine. 1994;73:110–8.
18. Kleinschmidt-DeMasters BK, Rojiani AM, Filley CM. Central
and extrapontine myelinolysis: then and now. J Neuropathol Exp
Neurol. 2006;65:1–11.
19. Lampl C, Yazdi K. Central pontine myelinolysis. Eur Neurol.
2002;47(1):3–10.
294 Neurocrit Care (2014) 20:287–295
123
20. Cuervas-Mons V, Martinez AJ, Dekker A, Starzl TE, Thiel DH.
Adult liver transplantation: an analysis of the early causes of
death in 40 consecutive cases. Hepatology. 1986;6:495–501.
21. Adams DH, Gunson B, Honigsberger L, et al. Neurological com-
plications following liver transplantation. Lancet. 1987;1:949–51.
22. Miller GM, Baker HL, Okazaki H, Whisnant JP. Central pontine
myelinolysis and its imitators: MR findings. Radiology.
1988;168:795–802.
23. Reyes J, Gayowski T, Fung J, Todo S, Alessiani M, Starzl TE.
Expressive dysphasia possibly related to FK 506 in two liver
transplant recipients. Transplantation. 1990;50:1043–5.
24. Bird GL, Meadows J, Goka J, Polson R, Williams R. Cyclo-
sporin-associated akinetic mutism and extrapyramidal syndrome
after liver transplantation. J Neurol Neurosurg Psychiatry.
1990;53:1068–71.
25. Boon AP, Carey MP, Adams DH, Buckels J, McMaster P. Central
pontine myelinolysis in liver transplantation. J Clin Pathol.
1991;44:909–14.
26. Burkhalter EL, Starzl TE, Van Thiel DH. Severe neurological
complications following orthotopic liver transplantation in patients
receiving FK 506 and Prednisone. J Hepatol. 1994;21:572–7.
27. Kabeer MH, Filo RS, Milgrom ML, et al. Central pontine mye-
linolysis following orthotopic liver transplant: association with
cyclosporin toxicity. Postgrad Med J. 1995;71(834):239–41.
28. Menger H, Jorg J. Outcome of central pontine and extrapontine
myelinolysis (n = 44). J Neurol. 1999;246:700–5.
29. Murdoch M, Chang M, McVicar J. Central pontine myelinolysis
after liver transplantation: a case report. Transpl Int. 1995;
8(5):399–402.
30. Rodriguez J, Benito-Leon J, Molina JA, Ramos A, Bermeo F.
Central Pontine myelinolysis associated with cyclosporine in
liver transplantation. Neurologia. 1998;13:437–40.
31. Buis CI, Wijdicks EFM. Serial magnetic resonance imaging of
central pontine myelinolysis. Liver Transplant. 2002;8:643–7.
32. Guo Y, Hu JH, Lin W, Zheng KH. Central pontine myelinolysis
after liver transplantation: MR diffusion, spectroscopy and per-
fusion findings. Magn Reson Imaging. 2006;24:1395–8.
33. Senzolo M, Ferronato C, Burra P. Neurologic complications after
solid organ transplantation. Transpl Int. 2009;22(3):269–78.
34. Bechstein WO. Neurotoxicity of calcineurin inhibitors: impact
and clinical management. Transpl Int. 2000;13(5):313–26.
35. Howard SA, Barletta JA, Klufas RA, Saad A, De Girolami U.
Best cases from the AFIP: osmotic demyelination syndrome.
Radiographics. 2009;29:933–8.
36. Chu K, Kang DW, Ko SB, Kim M. Diffusion-weighted MR
findings of central pontine and extrapontine myelinolysis. Acta
Neurol Scand. 2001;104:385–8.
37. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict
survival in patients with end-stage liver disease. Hepatology.
2001;33:464–70.
38. Ashrafian H, Davey D. A review of the causes of central pontine
myelinolysis: yet another apoptotic illness? Eur J Neurol.
2001;8:103–9.
39. Thurston JH, Hauhart RE, Nelson JS. Adaptive increases in
amino acids (taurine in particular), creatine, and electrolytes
prevent cerebral edema in chronically hyponatremic mice; rapid
correction (experimental model of central pontine myelinolysis)
causes dehydration and shrinkage of brain. Metab Brain Dis.
1987;2:223–41.
40. Brown WD. Osmotic demyelination disorders: central pontine
and extrapontine myelinolysis. Curr Opin Neurol. 2000;13:691–
7.
41. Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis,
clinical significance, and management. Hepatology. 2008;48:
1002–10.
42. Fukazawa K, Nishida S, Aguina L, Pretto E Jr. Central pontine
myelinolysis (CPM) associated with tacrolimus (FK506) after
liver transplantation. Ann Transplant. 2011;16(3):139–42.
Neurocrit Care (2014) 20:287–295 295
123
